Adaptive Biotechnologies Corporation (ADPT)

2,9250 +0,1350 (+4,84%) Ab 03:24PM EDT. Markt geöffnet.

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 709

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Julie Rubinstein	President & COO	721,04k	N/A	1972
Dr. Harlan S. Robins Ph.D.	Co-Founder & Chief Scientific Officer	711,09k	N/A	1973
Ms. Stacy L. Taylor	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1960
Ms. Mary Pat Lancelotta	Senior Vice President of MRD BioPharma	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Adaptive Biotechnologies Corporations ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.